A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
European Journal of Cancer2018Vol. 102, pp. 95–102
Citations Over TimeTop 10% of 2018 papers
Michele Reni, Silvia Zanon, Gianpaolo Balzano, Paolo Passoni, Chiara Pircher, Marta Chiaravalli, Clara Fugazza, Domenica Ceraulo, Roberto Nicoletti, Paolo Giorgio Arcidiacono, Marina Macchini, Umberto Peretti, R. Castoldi, Claudio Doglioni, Massimo Falconi, Stefano Partelli, Luca Gianni
Related Papers
- → Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer(2008)89 cited
- → Gemcitabine treatment enhances the activity of deoxycytidine kinase in periferial lymphocytes of patients with pancreatic cancer(2004)
- → Gemcitabine and capecitabine synergism and biomodulation with dipridamole in a mouse tumor model(2006)
- → Supplementary Figure 1 from The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase(2023)